MCP: Just drops of viper venom
pack a deadly punch
A bite from a lancehead viper can be fatal. Species in the family, among the most dangerous snakes in Central and South America, have venom that can disrupt blood clotting and cause hemorrhage, strokes and kidney failure.
Researchers at Brazil’s largest producer of anti-venoms have done a structural analysis of glycans modifying venom proteins in several species of lancehead. The report offers insight into the solubility and stability of toxic proteins from venom and into how venoms from different species vary. Scientists are working to map glycan structures back onto the proteins they modify.
Solange Serrano, a researcher at the Laboratory of Applied Toxicology at the in Sao Paulo, studies the protein toxins in lancehead venom. In in ͵͵ & Cellular Proteomics, scientists from Serrano’s laboratory, in collaboration with researchers at the , report on the sweet side of snake venom toxins.
The researchers looked at glycans, a group of sugar molecules attached in a complex chain, often with many branches, that can be attached to proteins. According to Serrano, most proteins in lancehead venom are modified with glycans, which can affect the proteins’ folding, stability and binding. But little is known about glycan structure in the venom.
Serrano’s graduate student Debora Andrade-Silva visited the laboratory of glycomics expert in New Hampshire to learn techniques for structural characterization of glycans. While there, Andrade-Silva and colleagues characterized the structure of 60 glycan chains in eight lancehead, or Bothrops, species’ venoms. The researchers isolated the glycans and analyzed them by mass spectrometry, breaking down each complex molecule into smaller, simpler ions. By piecing together the spectra of many such ions, they could tell which sugars were present and how they were linked into treelike glycan structures.
Lancehead venom contains nearly 100 milligrams of protein per milliliter of liquid. At this concentration, protein solutions tend to become viscous or form gels. Analyzing the structures of glycans attached to the proteins, the researchers found that a disproportionate number were tipped with sialic acid, a sugar with a negative charge.
“Glycans containing sialic acid may help in venom solubility and increase toxin half-life,” Serrano said.
Sialic acid on a toxic enzyme may also bind to host proteins called siglecs, pulling the enzyme closer to target cells for greater effect; this has been observed in other types of venom.
While Serrano’s group researches venom composition, the applications are close to home. Another department of the Instituto Butantan produces most of the anti-venom available in Brazil. Serrano said she hopes that basic research into venom toxins will help researchers develop improved treatments for envenomation.
“The antivenoms do a reasonable job, but they are not so good at neutralizing the local effects of snakebite,” Serrano said.
These effects, including swelling, hemorrhage and necrosis, can be so severe that doctors must sometimes amputate bitten limbs. Better understanding of how venom differs between snake species could improve the efficacy of anti-venom treatment.
Andrade-Silva and Serrano are working to map the structures from the glycan inventory back onto the proteins they modify. Because some venom proteins have been repurposed as medicines, knowing more about how glycosylation helps each protein fold, hold its shape and attach to binding partners may have applications in biotechnology.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Guiding grocery carts to shape healthy habits
Robert “Nate” Helsley will receive the Walter A. Shaw Young Investigator in Lipid Research Award at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.
Quantifying how proteins in microbe and host interact
“To develop better vaccines, we need new methods and a better understanding of the antibody responses that develop in immune individuals,” author Johan Malmström said.
Leading the charge for gender equity
Nicole Woitowich will receive the ASBMB Emerging Leadership Award at the 2025 ASBMB Annual meeting, April 12–15 in Chicago.
CRISPR gene editing: Moving closer to home
With the first medical therapy approved, there’s a lot going on in the genome editing field, including the discovery of CRISPR-like DNA-snippers called Fanzors in an odd menagerie of eukaryotic critters.
Finding a missing piece for neurodegenerative disease research
Ursula Jakob and a team at the University of Michigan have found that the molecule polyphosphate could be what scientists call the “mystery density” inside fibrils associated with Alzheimer’s, Parkinson’s and related conditions.
From the journals: JLR
Enzymes as a therapeutic target for liver disease. Role of AMPK in chronic liver disease Zebrafish as a model for retinal dysfunction. Read about the recent JLR papers on these topics.